Clinical trial

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

NCT02090114

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-08-25

PhasePHASE2

Study timeline

Study start (actual)2014-08-25Date precision: day

Registry last updated2022-06-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

Testosterone cypionateDRUG · verified · RxNorm: testosterone cypionate

Testosterone EnanthateDRUG · verified · RxNorm: testosterone enanthate

Abiraterone acetateDRUG · verified · RxNorm: abiraterone acetate

EnzalutamideDRUG · verified · RxNorm: enzalutamide

Sponsors & collaborators

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinslead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

BaltimoreMaryland, United States1 Washington D.C.District of Columbia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02090114 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.